8x8 Inc vs NeoGenomics Inc. Common Stock — how do they compare? 8x8 Inc trades at $2.02 (market cap $296.09M), while NeoGenomics Inc. Common Stock trades at $16.85 (market cap $2.14B). The key difference: NeoGenomics Inc. Common Stock is far larger — about 7.2× 8x8 Inc's market cap, and NeoGenomics Inc. Common Stock is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold 8x8 Inc for 16 Days and NeoGenomics Inc. Common Stock for 0 Days on average.
| EGHT | NEO | |
|---|---|---|
Market Cap | $296.09M | $2.14B |
Volume | 1,073,599 | 2,228,400 |
Sector | Technology | Health |
52-Week High | $2.76 | $19.91 |
52-Week Low | $1.59 | $7.19 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $563.02M | $2.44B |
Signals from Pluang's Aura AI — not financial advice
EGHT trades at $2.05, up 0.49% today, with a mixed technical picture showing bullish oscillators but bearish moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected profitability in 2026. Recent news highlights cost-saving customer implementations and AI platform growth, while analyst consensus remains divided with a $19.77 price target representing significant upside potential from current levels.
The stock presents a high-risk, high-reward opportunity with substantial upside if the company achieves projected profitability, though current negative earnings and high debt levels pose execution risks. Institutional interest is growing with recent position increases, but the stock requires careful monitoring of Q3 2026 earnings results and debt management progress.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →